Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-04
DOI
10.1038/s41598-018-31913-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study
- (2017) Naoto Takahashi et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- In VivoKnockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
- (2017) Nobumichi Ohoka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands
- (2017) Norihito Shibata et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds
- (2017) Kwok-Ho Chan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression
- (2017) Bing Zhou et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structural basis of PROTAC cooperative recognition for selective protein degradation
- (2017) Morgan S Gadd et al. Nature Chemical Biology
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- Targeting the Allosteric Site of Oncoprotein BCR-ABL as an Alternative Strategy for Effective Target Protein Degradation
- (2017) Kenichiro Shimokawa et al. ACS Medicinal Chemistry Letters
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand
- (2016) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
- (2016) Nobumichi Ohoka et al. CURRENT CANCER DRUG TARGETS
- Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules
- (2016) Keiichiro Okuhira et al. MOLECULAR PHARMACOLOGY
- PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
- (2016) Kanak Raina et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
- (2015) Dennis L. Buckley et al. ACS Chemical Biology
- Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
- (2015) Michael Zengerle et al. ACS Chemical Biology
- Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL
- (2015) Ashton C. Lai et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
- (2015) Jing Lu et al. CHEMISTRY & BIOLOGY
- Catalytic in vivo protein knockdown by small-molecule PROTACs
- (2015) Daniel P Bondeson et al. Nature Chemical Biology
- Degradation of HaloTag-fused nuclear proteins using bestatin-HaloTag ligand hybrid molecules
- (2015) Shusuke Tomoshige et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Phthalimide conjugation as a strategy for in vivo target protein degradation
- (2015) G. E. Winter et al. SCIENCE
- Fluorescent Visualization of Src by Using Dasatinib-BODIPY
- (2014) Michael L. Vetter et al. CHEMBIOCHEM
- Structure-Guided Design and Optimization of Small Molecules Targeting the Protein–Protein Interaction between the von Hippel–Lindau (VHL) E3 Ubiquitin Ligase and the Hypoxia Inducible Factor (HIF) Alpha Subunit with in Vitro Nanomolar Affinities
- (2014) Carles Galdeano et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- Cancer cell death induced by novel small molecules degrading the TACC3 protein via the ubiquitin–proteasome pathway
- (2014) N Ohoka et al. Cell Death & Disease
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells
- (2013) Keiichiro Okuhira et al. CANCER SCIENCE
- Double protein knockdown of cIAP1 and CRABP-II using a hybrid molecule consisting of ATRA and IAPs antagonist
- (2012) Yukihiro Itoh et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy
- (2011) Yosuke Demizu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Specific degradation of CRABP-II via cIAP1-mediated ubiquitylation induced by hybrid molecules that crosslink cIAP1 and the target protein
- (2011) Keiichiro Okuhira et al. FEBS LETTERS
- Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR , Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants
- (2010) E. Weisberg et al. BLOOD
- Protein Knockdown Using Methyl Bestatin−Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
- (2010) Yukihiro Itoh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Smac mimetics: implications for enhancement of targeted therapies in leukemia
- (2010) E Weisberg et al. LEUKEMIA
- Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
- (2008) Ashley R. Schneekloth et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- Development of an Aryl Hydrocarbon Receptor Antagonist Using the Proteolysis-Targeting Chimeric Molecules Approach: A Potential Tool for Chemoprevention
- (2008) D. Puppala et al. MOLECULAR PHARMACOLOGY
- Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
- (2008) A Rodriguez-Gonzalez et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More